A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder

Journal of Clinical Psychiatry

Volumn 74, Issue 8, 2013, Pages

  Yoo, Hanik K ^a   Joung, Yoo Sook ^a   Lee, Jeong Seop ^e   Song, Dong Ho ^b   Lee, Young Sik ^c   Kim, Jae Won ^d   Kim, Bung Nyun ^d   Cho, Soo Churl ^d  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; AGE DISTRIBUTION; AKATHISIA; ANOREXIA; BODY MASS; CHILD; CHILD HEALTH; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; INCREASED APPETITE; INSOMNIA; INSULIN BLOOD LEVEL; IRRITABILITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOCYTE; NAUSEA; NEUROPSYCHOLOGICAL TEST; NEUTROPHIL COUNT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; YALE GLOBAL TIC SEVERITY SCALE;

EID: 84883143879     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08189     Document Type: Review

References (40)

1. Rampello L, Alvano A, Battaglia G, et al. Tic disorders: from pathophysiology to treatment. J Neurol. 2006;253(1):1-15.
2. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997;154(8):1057-1062.
3. Gilbert DL, Batterson JR, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43(2):206-214.
4. Yoo HK, Lee JS, Paik KW, et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20(3):127-135.
5. Barzman D, Gernert B, Delbello M. Quetiapine for chronic motor tic disorder. Am J Psychiatry. 2004;161(7):1307.
6. Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry. 2001;62(4):290-294.
7. Cui YH, Zheng Y, Yang YP, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China. J Child Adolesc Psychopharmacol. 2010;20(4):291-298.
8. Seo WS, Sung HM, Sea HS, et al. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol. 2008;18(2):197-205.
9. Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68(7):1088-1093.
10. Yoo HK, Kim JY, Kim CY. A pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2006;16(4):505-506.
11. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649-666.
12. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Cohen DJ, ed. Tourette's Syndrome and Tic Disorders. New York, NY: John Wiley & Sons; 1988:55-78.
13. Kim YS, Cheon KA, Kim BN, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J. 2004;45(1):81-89.
14. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28(4):566-573.
15. Park KS, Yoon JR, Park HF, et al. Development of the Korean Educational Development Institute Wechsler Intelligence Scale for Children-Revised (KEDI-WISC-R), Individual Intelligence Test for Korean Children. Seoul, South Korea: Korean Educational Development Institute; 1986.
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(s212):11-19.
17. Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry. 1985;42(9):874-878.
18. Guy M, ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: Nationalt Institute of Mental Health; 1976:534-537.
19. Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509-515.
20. Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol. 2009;19(6):623-633.
21. Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol. 2009;19(4):441-447.
22. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, doubleblind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441-1451.
23. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008;165(11):1432-1441.
24. Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540.
25. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry. 1978;135(5):585-587.
26. Dion Y, Annable L, Sandor P, et al. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22(1):31-39.
27. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130-1135.
28. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-299.
29. Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1991;48(4):324-328.
30. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074.
31. Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25(6):325-332.
32. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317-320.
33. Du YS, Li HF, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry. 2008;42(9):807-813.
34. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989;46(8):722-730.
35. Sowell ER, Thompson PM, Holmes CJ, et al. Localizing age-related changes in brain structure between childhood and adolescence using statistical parametric mapping. Neuroimage. 1999;9(6 pt 1):587-597.
36. Sowell ER, Thompson PM, Holmes CJ, et al. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999;2(10):859-861.
37. Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Role of atypical opiates in OCD: experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berl). 2007;190(2):221-231.
38. Díaz-Anzaldúa A, Joober R, Rivière JB, et al; Montreal Tourette Syndrome Study Group. Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. Mol Psychiatry. 2004;9(3):272-277.
39. Gilbert DL, Sethuraman G, Sine L, et al. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000;54(6):1310-1315.
40. Barrett B, Muller D, Rakel D, et al. Placebo, meaning, and health. Perspect Biol Med. 2006;49(2):178-198.